Content about Treatment of bipolar disorder

March 31, 2014

The Food and Drug Administration on Friday approved Topamax (topiramate) for prevention of migraine headaches in adolescents ages 12 years to 17 years.

SILVER SPRING, Md. — The Food and Drug Administration on Friday approved Topamax (topiramate) for prevention of migraine headaches in adolescents ages 12 years to 17 years. This is the first FDA approval of a drug for migraine prevention in this age group. 

The medication is taken on a daily basis to reduce the frequency of migraine headaches.

Topamax was first approved by the FDA in 1996 to prevent seizures. It was approved for migraine prevention in adults in 2004.

March 18, 2014

A new study published in the March 18 journal Annals of Internal Medicine raises questions about current guidelines which generally restrict the consumption of saturated fats and encourage consumption of polyunsaturated fats, or fish oils, to prevent heart disease.

CAMBRIDGE, England — A new study published in the March 18 journal Annals of Internal Medicine raises questions about current guidelines which generally restrict the consumption of saturated fats and encourage consumption of polyunsaturated fats, or fish oils, to prevent heart disease. 

"These are interesting results that potentially stimulate new lines of scientific inquiry and encourage careful reappraisal of our current nutritional guidelines," suggested Rajiv Chowdhury, lead author of the research at the University of Cambridge.

March 12, 2014

Upsher-Smith has received approval from the Food and Drug Administration for Qudexy XR (topiramate) extended-release capsules, a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic profile.

MAPLE GROVE, Minn. — Upsher-Smith has received approval from the Food and Drug Administration for Qudexy XR (topiramate) extended-release capsules, a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic profile.

Qudexy XR will be available to patients in second quarter 2014.

March 7, 2014

A study published online Friday shows that the omega-3 fatty acids EPA and DHA — commonly found in fatty fish and fish oil supplements — are as effective, if not more effective, in lowering blood pressure as some of the commonly recommended lifestyle changes like increasing physical activity and restricting alcohol and sodium intake.

SALT LAKE CITY — A study published online Friday shows that the omega-3 fatty acids EPA and DHA — commonly found in fatty fish and fish oil supplements — are as effective, if not more effective, in lowering blood pressure as some of the commonly recommended lifestyle changes like increasing physical activity and restricting alcohol and sodium intake. The findings, released by the American Journal of Hypertension, are good news, especially for those with elevated blood pressure.

February 27, 2014

LED Technologies announced has formed an alliance with Kathy Ireland Worldwide to develop reVive Light Therapy skin care devices for anti-aging; uneven skin tone and hyperpigmantation; acne; and skin healing.

DENVER — LED Technologies announced has formed an alliance with Kathy Ireland Worldwide to develop reVive Light Therapy skin care devices for anti-aging; uneven skin tone and hyperpigmantation; acne; and skin healing.

The FDA-approved reVive Light Therapy features a collection that offers full face as well as hand-held light devices, across a full range LED Light Modalities.

January 20, 2014

Nordic Naturals earlier this year launched Omega Boost, featuring 525 mg of omega-3s per serving.

WATSONVILLE, Calif. — Nordic Naturals earlier this year launched Omega Boost, featuring 525 mg of omega-3s per serving. Sugar-free and sweetened with xylitol, Omega Boost is made from purified fish oil from anchovies and sardines, and offers fast absorption of the omega-3 fats EPA and DHA. Each 6-oz. bottle contains 35 servings, and has a convenient flip cap for easy pouring. 

January 20, 2014

Higher levels of melatonin, a hormone involved in the sleep-wake cycle, may decrease the risk of developing advanced prostate cancer, according to results presented here at the AACR-Prostate Cancer Foundation Conference on Advances in Prostate Cancer Research, held Jan. 18-21.

SAN DIEGO — Higher levels of melatonin, a hormone involved in the sleep-wake cycle, may decrease the risk of developing advanced prostate cancer, according to results presented here at the AACR-Prostate Cancer Foundation Conference on Advances in Prostate Cancer Research, held Jan. 18-21.

December 9, 2013

An experimental drug under development by Upsher-Smith Labs for epilepsy is able to reduce seizures in patients with mild to moderate side effects, according to results of a late-stage clinical trial announced Monday.

MAPLE GROVE, Minn. — An experimental drug under development by Upsher-Smith Labs for epilepsy is able to reduce seizures in patients with mild to moderate side effects, according to results of a late-stage clinical trial announced Monday.

November 18, 2013

Drug maker Upsher-Smith Labs will present data from a late-stage trial of a drug for treating epilepsy, the company said Monday.

MAPLE GROVE, Minn. – Drug maker Upsher-Smith Labs will present data from a late-stage trial of a drug for treating epilepsy, the company said Monday.

September 25, 2013

Oceans Omega on Wednesday announced the launch of Omega-3 fortified liquid health shots. Currently sold under the Omega Infusion brand, the 2-oz., single-serving and zero-calorie health shots contain 250 mg of omega-3s (EPA and DHA).

PARAMUS, N.J. — Oceans Omega on Wednesday announced the launch of Omega-3 fortified liquid health shots. Currently sold under the Omega Infusion brand, the 2-oz., single-serving and zero-calorie health shots contain 250 mg of omega-3s (EPA and DHA).  

They will be available in three flavors, including peach mango, raspberry lemon and pink grapefruit. 

Research shows that consumers are actively looking for Omega-3 fortified food and beverages, the company stated.

August 23, 2013

Indian drug maker Dr. Reddy's Labs has launched a generic treatment for epilepsy, the company said.

HYDERABAD, India — Indian drug maker Dr. Reddy's Labs has launched a generic treatment for epilepsy, the company said.

Dr. Reddy's announced the launch of divalproex sodium extended-release tablets in the 250-mg and 500-mg strengths, used to treat epileptic seizures. The 250-mg tablets are available in bottle count sizes of 100, while the 500-mg tablets are available in sizes of 100 and 500.

August 19, 2013

The Food and Drug Administration has approved a new epilepsy drug made by Supernus Pharmaceuticals, the company said.

ROCKVILLE, Md. — The Food and Drug Administration has approved a new epilepsy drug made by Supernus Pharmaceuticals, the company said Monday.

Supernus announced the approval of Trokendi XR, a once-daily, extended-release formulation of the drug topiramate. As part of the approval, the FDA granted Supernus a waiver for some of the requirements for studies of the drug in children and a deferral for submission of other post-marketing data due in 2019, followed by clinical assessments in 2025.

July 12, 2013

A second large, prospective study by scientists at Fred Hutchinson Cancer Research Center that claimed to confirm the link between high blood concentrations of omega-3 fatty acids and an increased risk of prostate cancer drew a stark industry response from supplement trade associations.

SEATTLE — A second large, prospective study by scientists at Fred Hutchinson Cancer Research Center released on Wednesday that claimed to confirm the link between high blood concentrations of omega-3 fatty acids and an increased risk of prostate cancer drew a stark industry response from supplement trade associations.

May 29, 2013

An Indiana University study has found that a unique omega-3 supplement derived from the New Zealand green-lipped mussel significantly improved lung function and reduced airway inflammation in asthmatics who experience exercise-induced bronchoconstriction, also called exercise-induced asthma.

BLOOMINGTON, Ind. — An Indiana University study has found that a unique omega-3 supplement derived from the New Zealand green-lipped mussel significantly improved lung function and reduced airway inflammation in asthmatics who experience exercise-induced bronchoconstriction, also called exercise-induced asthma.

March 8, 2013

Oceans Omega launched its omega-3 EPA/DHA enhanced water product, branded Omega Infusion, into 100 H-E-B stores with Healthy Living Departments, the company announced.

PARAMUS, N.J. — Oceans Omega launched its omega-3 EPA/DHA enhanced water product, branded Omega Infusion, into 100 H-E-B stores with Healthy Living Departments, the company announced.

February 27, 2013

Nordic Naturals and Lipid Technologies on Tuesday developed a partnership to ensure that practitioners have easy access to the Holman Omega-3 Blood Spot Test for their patients.

WATSONVILLE, Calif. — Nordic Naturals and Lipid Technologies on Tuesday developed a partnership to ensure that practitioners have easy access to the Holman Omega-3 Blood Spot Test for their patients. The Holman Omega-3 Blood Spot Test delivers a fast, easy and accurate measurement of a person’s omega-3 levels, which can aid in making informed choices about diet and supplementation. 

January 29, 2013

Oceans Omega launched Omega Infusion, an omega-3 EPA/DHA enhanced water product with initial placement within Giant Food.

PARAMUS, N.J. — Oceans Omega on Monday launched Omega Infusion, an omega-3 EPA/DHA enhanced water product with initial placement within Giant Food.

"Delivering heart healthy omega-3 fatty acids in enhanced water is something we've been developing for years," stated Volker Berl, chief technology officer Oceans Omega. "Our proprietary delivery system is transforming the beverage industry by including ingredients like Omega-3 EPA/DHA."

November 14, 2012

The Community Specialty Pharmacy Network has entered a contract with Dara BioSciences to distribute a nonsteroidal anti-estrogen product.

DREXEL HILL, Pa. — The Community Specialty Pharmacy Network has entered a contract with Dara BioSciences to distribute a nonsteroidal anti-estrogen product.

CSPN announced the agreement with Dara to distribute Soltamox (tamoxifen) solution for oral administration. The drug, a treatment for breast cancer, is for patients who have difficulty swallowing pills.

September 12, 2012

As part of a meta-analysis spanning 70,000 patients, a study published in the Sept. 12 issue of JAMA determined supplementation with omega-3 fish oils was not associated with a lower risk in heart disease.

CHICAGO — As part of a meta-analysis spanning 70,000 patients, a study published in the Sept. 12 issue of JAMA determined supplementation with omega-3 fish oils was not associated with a lower risk in heart disease. Lead researcher Evangelos Rizos of the University Hospital of Ioannina in Greece, concluded that omega-3 supplement recommendations may be overblown.

August 14, 2012

Nordic Naturals on Tuesday rolled out a brand new look across its professional product line with a new classification system to better assist selection.

WATSONVILLE, Calif. — Nordic Naturals on Tuesday rolled out a brand new look across its professional product line with a new classification system to better assist selection.

"These labels have been developed with input from professional healthcare practitioners in mind," Nordic Naturals chief medical officer Keri Marshall said. "With more than 40 professional products, our new label design will make dosing and product selection convenient for the practitioner, and ensure the best possible experience for patients."

August 10, 2012

Mylan has launched a generic drug used to treat sleep disorders, the company said Friday.

PITTSBURGH — Mylan has launched a generic drug used to treat sleep disorders, the company said Friday.

The generic drug maker announced the launch of modafinil tablets in the 100-mg and 200-mg strengths. The drug is a generic version of Provigil, made by Cephalon — a company that Teva Pharmaceutical Industries acquired last year — and used to treat narcolepsy, obstructive sleep apnea and shift work disorder.

June 26, 2012

The Food and Drug Administration has given tentative approval to Supernus Pharmaceuticals for a drug to treat epilepsy, the company said Tuesday.

ROCKVILLE, Md. — The Food and Drug Administration has given tentative approval to Supernus Pharmaceuticals for a drug to treat epilepsy, the company said Tuesday.

Supernus announced the tentative approval was given to Trokendi XR (topiramate), a once-daily treatment for the seizure disorder. The company said final approval was conditioned on resolution of market exclusivity issues concerning certain pediatric populations.

June 18, 2012

Greenstone, the generic pharmaceutical subsidiary of Pfizer, has launched olanzapine tablets.

PEAPACK, N.J. — Greenstone, the generic pharmaceutical subsidiary of Pfizer, has launched olanzapine tablets.

The drug, which is a generic version of Zyprexa — an Eli Lilly drug used to treat psychiatric disorders — in the 2.5-mg, 5-mg, 7.5-mg, 10-mg, 15-mg and 20-mg strengths.

Generic and branded versions of the drug had sales of about $3.28 billion during the 12-month period ended in January, according to IMS Health.

June 12, 2012

Nordic Naturals on Tuesday introduced Algae Omega, a solution for vegetarians seeking the health benefits of marine omega-3s. Made from sustainably sourced microalgae and available in both soft gels and liquid, the product offers an algae-based source of beneficial marine omega-3 essential fatty acids without the use of fish.

WATSONVILLE, Calif. — Nordic Naturals on Tuesday introduced Algae Omega, a solution for vegetarians seeking the health benefits of marine omega-3s. Made from sustainably sourced microalgae and available in both soft gels and liquid, the product offers an algae-based source of beneficial marine omega-3 essential fatty acids without the use of fish.

"We formulated Algae Omega with vegetarians in mind, and for anyone wanting a readily available, high-quality source of EPA and DHA from a non-fish source," stated Joar Opheim, CEO of Nordic Naturals.

May 8, 2012

A generic version of a schizophrenia drug made by Otsuka Holdings and Bristol-Myers Squibb can't be launched until April 2015, according to published reports.

NEW YORK — A generic version of a schizophrenia drug made by Otsuka Holdings and Bristol-Myers Squibb can't be launched until April 2015, according to published reports.

Bloomberg reported that the U.S. Court of Appeals for the Federal Circuit upheld the validity of patents covering Abilify (aripiprazole) in the two companies' lawsuit against Teva Pharmaceutical Industries and Apotex.

According to IMS Health, Abilify was the fourth top-selling drug in the United States in 2011, with sales of $5.2 billion.